Global Clostridium Difficile Treatment Industry

Global Clostridium Difficile Treatment Industry

  • April 2021 •
  • 125 pages •
  • Report ID: 6040517 •
  • Format: PDF
Abstract:
- Global Clostridium Difficile Treatment Market to Reach $1.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Clostridium Difficile Treatment estimated at US$878.9 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at a CAGR of 5.1% over the analysis period 2020-2027. Metronidazol, one of the segments analyzed in the report, is projected to record a 5.8% CAGR and reach US$561.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Vancomycin segment is readjusted to a revised 4.7% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $259.1 Million, While China is Forecast to Grow at 4.7% CAGR
- The Clostridium Difficile Treatment market in the U.S. is estimated at US$259.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$219.3 Million by the year 2027 trailing a CAGR of 4.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.
- Fidaxomicin Segment to Record 4.5% CAGR
- In the global Fidaxomicin segment, USA, Canada, Japan, China and Europe will drive the 4.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$173.9 Million in the year 2020 will reach a projected size of US$237.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$142.7 Million by the year 2027.

- Select Competitors (Total 38 Featured) -
  • Actelion Pharmaceuticals Ltd.
  • Astellas Pharma, Inc.
  • Da Volterra
  • Finch Therapeutics Group, Inc.
  • Immuron Ltd.
  • Merck & Co., Inc.
  • MGB Biopharma
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Rebiotix, Inc.
  • Romark L.C.
  • Sanofi Pasteur SA
  • Seres Therapeutics, Inc.
  • Summit Therapeutics Plc
  • Synthetic Biologics, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Valneva SE